Skip to main content
Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc. — Investor Relations & Filings

Ticker · ACRS ISIN · US00461U1051 LEI · 5493000B2LQ9QTW1DF52 US Manufacturing
Open in API
Filings indexed 844 across all filing types
Latest filing 2023-09-05 Major Shareholding Noti…
Country US United States of America
Listing US ACRS

About Aclaris Therapeutics, Inc.

https://www.aclaristx.com/

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel drug candidates for immuno-inflammatory diseases. The company leverages its core expertise in drug discovery, development, and kinase inhibition to create a pipeline of both small and large molecule drugs. Aclaris focuses on translating scientific discovery into innovative therapies to address the needs of patients with underserved conditions.

Recent filings

Filing Released Lang Actions
SC 13G
Major Shareholding Notification
2023-09-05 English
FORM 4 SUBMISSION
Director's Dealing
2023-08-28 English
FORM 4 SUBMISSION
Director's Dealing
2023-08-22 English
Regulatory Filings 2023
Regulatory Filings
2023-08-21 English
10-Q
Interim / Quarterly Report Q2 2023
2023-08-07 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and references a press release announcing financial results for the quarter and six months ended June 30, 2023. The document itself is short (3953 characters) and primarily serves to announce the release of financial results via a press release (Exhibit 99.1). It does not contain detailed financial statements or substantive financial data itself, but rather points to the press release. According to the "Menu vs Meal" rule, such a document is an announcement of a report rather than the report itself. Therefore, the appropriate classification is Earnings Release (ER), as it is the initial announcement of quarterly financial results, but since the document is a Form 8-K announcing the earnings release, it fits best as ER rather than a full Interim Report (IR).
2023-08-07 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.